What is CJC-1295?

CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analog built from the active hGRF(1-29) sequence. Its amino-acid substitutions and albumin-binding extension are designed to resist breakdown and keep the pituitary GHRH signal active longer than native GHRH fragments. [3][16]

The defining feature is its albumin-binding tail. After injection, that group can attach to circulating albumin, which acts like a carrier protein in blood; this is why CJC-1295 is discussed as the long-acting form while Modified GRF 1-29 is treated as shorter acting. [3][16]

Biologically, CJC-1295 does not replace growth hormone directly. It stimulates the pituitary GHRH receptor pathway, and human studies show downstream GH and IGF-1 biomarker increases when the pituitary GH axis can respond. [1][2]

The naming can be messy. CJC-1295, CJC-1295 without DAC, Modified GRF 1-29, and blends with GH secretagogues are not interchangeable; this page uses CJC-1295 to mean the long-acting albumin-binding form unless a section says otherwise. [16][3]

What CJC-1295 is investigated for

CJC-1295 evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

GH-axis stimulation and IGF-1 biomarker response

Injectable

68% Moderate

This is the best-supported CJC-1295 claim: human evidence shows sustained GH and IGF-1 biomarker response after subcutaneous dosing. [1][2]

Human evidence

In healthy adults, subcutaneous CJC-1295 produced dose-dependent mean plasma GH increases of 2- to 10-fold for six days or more and mean plasma IGF-1 increases of 1.5- to 3-fold for 9-11 days after single dosing. A separate study found increased trough and mean GH with preserved pulsatility. [1][2]

Animal / mechanistic evidence

Preclinical work identified CJC-1295 as a long-lasting hGRF(1-29) analog that conjugates to albumin and remains detectable longer than native GHRH fragments in rats. Mouse GHRH-knockout work supports GH-axis biological activity in a deficiency model. [3][5]

Lean-mass and fat-loss support

Injectable

45% Preliminary

Lean-mass and fat-loss support are biologically plausible for CJC-1295 because the peptide sustains GH and IGF-1 signaling, but direct human outcome evidence remains weak. [1][5]

Human evidence

Interest centers on lean-mass support, fat-mass changes, and weight-trend changes downstream of GH and IGF-1 signaling. Human CJC-1295 studies show sustained GH and IGF-1 biomarker increases, but they did not establish controlled DEXA, waist, visceral-fat, or fat-loss outcomes. [1][2]

Animal / mechanistic evidence

In a GHRH-knockout mouse deficiency model, daily CJC-1295 supported normal growth and tissue-mass-related measures. That strengthens the GH-axis rationale, but it is not the same as healthy-adult lean-mass or fat-loss evidence. [5]

Exercise recovery and training adaptation

Injectable

18% Insufficient

Recovery is commonly discussed with CJC-1295, but it should be shown as an indirect GH-axis claim until outcome-specific human evidence is available. [1][4]

Human evidence

No reviewed controlled human CJC-1295 trial shows faster exercise recovery, injury recovery, strength gains, or training adaptation. Human support is indirect: the peptide can raise GH and IGF-1 biomarkers that readers associate with repair and recovery biology. [1][4]

Animal / mechanistic evidence

Animal and mechanistic work supports prolonged GHRH signaling and GH-axis activity, but the reviewed CJC-1295 animal data are not sports-injury or training-adaptation studies. [3][5]

Sleep quality

Injectable

16% Insufficient

Sleep quality is a common tracking claim for CJC-1295, but the current evidence supports GH-axis physiology, not a proven sleep benefit. [2]

Human evidence

CJC-1295 has not shown controlled sleep-quality outcomes in the reviewed human evidence. The sleep rationale comes from overnight GH physiology and preserved GH pulsatility, not from validated sleep endpoints. [2]

Animal / mechanistic evidence

The reviewed preclinical evidence supports CJC-1295 duration and GH-axis activity rather than sleep architecture, sleep latency, REM, deep sleep, or insomnia outcomes. [3][5]

Anti-aging and vitality support

Injectable

14% Insufficient

Anti-aging and vitality belong on the page because readers search for them, but they should remain low-confidence outcome claims rather than proven benefits. [1][4]

Human evidence

Human CJC-1295 studies show endocrine biomarker changes, not longevity, healthspan, age reversal, skin aging, frailty, or vitality outcomes. Anti-aging claims are downstream interpretations that need their own human outcome data. [1][4]

Animal / mechanistic evidence

The reviewed animal evidence supports GH-axis signaling and albumin-linked duration. It does not establish lifespan, healthspan, senescence, or age-related functional benefits. [3][5]

Evidence snapshot

Overall confidence

Moderate

65%

CJC-1295 has stronger human biomarker evidence than many research peptides, but weaker clinical-outcome evidence than approved GH-axis drugs. The best-supported statement is that it can sustain GH and IGF-1 biomarker increases after subcutaneous administration. [1][2][17]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

70%

Human evidence

Moderate

Human pharmacodynamic support is strongest for GH and IGF-1 biomarkers: GH rose for six days or more, IGF-1 rose for 9-11 days after single dosing, and repeated dosing kept mean IGF-1 above baseline for up to 28 days. [1]

50%

Animal / preclinical

Limited

Animal studies support the albumin-binding GHRH mechanism. Rat work identified CJC-1295 as a long-lasting hGRF(1-29) analog, and GHRH-knockout mice treated once daily maintained normal growth and body composition. This supports GH-axis pharmacology, not human outcome claims. [3][5]

68%

Mechanism support

Moderate

Mechanistic support is coherent: CJC-1295 is a modified GHRH analog, the DAC form binds albumin, and human studies show GH-axis activation. FDA notes that DAC and non-DAC forms should not be treated as interchangeable. [3][2][16]

Forms & administration

CJC-1295 is primarily discussed as a subcutaneous, long-acting GHRH analog. Route, albumin-binding form, concentration, product quality, and monitoring matter because sustained GH/IGF-1 signaling depends on systemic exposure. [1][16][15]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common CJC-1295 protocols usually use 2 mg per dose. [1][16]

Frequency

Common CJC-1295 protocols usually use 2-3 doses per week because the albumin-binding form is long acting. [1][16]

Timing Considerations

Before-bed timing is common in GH-oriented schedules because GH physiology and overnight pulses drive the rationale. Keep timing consistent when comparing sleep, recovery, and lab trends over a cycle. [2][1]

Cycle Length

Common CJC-1295 cycles usually run 8-12 weeks before reassessment. Use that window to compare labs, body-composition trend, sleep notes, recovery notes, and adverse effects against baseline. [1]

Protocol Notes

Track one claim at a time. GH/IGF-1 lab changes, body composition, recovery, sleep, and perceived vitality are different endpoints, and injectable product quality can change the safety picture. [4][15][16]

What to expect

First week

Early sustained GH and IGF-1 biomarker elevation after subcutaneous dosing, with practical notes around sleep, recovery, water retention, and appetite. [1][2]

Days 9-11

Persistent mean plasma IGF-1 increases after a single CJC-1295 dose, which is why albumin-binding CJC-1295 is scheduled differently from short-acting GHRH analogs. [1]

Weeks 4-12

Sustained GH/IGF-1 lab movement, weight trend, body-composition notes, sleep, training tolerance, and recovery patterns against baseline. [1][15]

After stopping

Gradual return-toward-baseline pattern for GH/IGF-1 biomarkers, weight, sleep notes, and training markers after long-acting exposure ends. [1][15]

Safety profile

CJC-1295 safety should be treated as endocrine-active, route-specific, and unresolved for long-term non-study use. Early human studies reported no serious adverse reactions, but FDA later identified serious adverse events associated with CJC-1295, limited clinical data, and peptide compounding concerns around immunogenicity, impurities, and API characterization. [1][15][16]

Common side effects

Injection-site pain or swelling [16]
Flushing or warmth [15]
Low blood pressure [15]
Faster heart rate [15]
Headache [1][16]
Gastrointestinal symptoms [1][16]

Cautions

Endocrine medical supervision [1][2]
Unapproved product quality [15][16]
Prohibited in sport [18]

What we don't know

Decision-changing unknowns include long-term safety, repeated non-study use, product interchangeability, DAC versus no-DAC risk differences, cancer- or growth-factor-sensitive conditions, special-population safety, and whether outcome benefits justify endocrine exposure. [15][16]

Who CJC-1295 is not for

Route-specific avoid and medical-review notes:

Competitive athletes
Competitive athletes should avoid CJC-1295 unless their anti-doping authority provides route-specific written clearance. WADA lists CJC-1295 as prohibited under growth hormone releasing factors. [18]
Endocrine disease or glucose dysregulation
Medical review is needed in endocrine disease, diabetes, insulin resistance, or unexplained abnormal IGF-1/GH-related labs because CJC-1295 acts through the GH/IGF-1 axis. [1][2]
Cancer or growth-factor-sensitive conditions
This is a medical-review caution, not a documented CJC-1295 cancer-outcome finding. Because the peptide raises IGF-1 biomarkers, growth-factor-sensitive histories should not be handled through self-directed use. [1][15]
Pregnancy, breastfeeding, or pediatric use
Pregnancy, breastfeeding, and pediatric use are not supported by route-specific CJC-1295 safety data. [15][16]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Other GH-axis drugs or secretagogues
This is a theoretical additive-exposure caution. Combining CJC-1295 with other GH-axis agents, growth hormone, GHRPs, or secretagogues may make GH/IGF-1 exposure and side-effect interpretation harder to manage. [1][2][15]
Glucose-active medications
This is a theoretical endocrine-monitoring caution. Because GH/IGF-1 signaling intersects with metabolic regulation, people using insulin, diabetes drugs, or weight-management medications need clinician review rather than app-only scheduling. [1]

Pairing notes

Commonly included in these stacks

CJC-1295 / Ipamorelin

CJC-1295 / Ipamorelin is a long-acting GH-axis stack built around a GHRH analog and a selective ghrelin-receptor growth-hormone secretagogue. The practical rationale is dual upstream stimulation of the GH/IGF-1 axis.

CJC-1295Ipamorelin

Related peptides

CJC-1295 (no DAC)

Regulatory status

United States

United States: not FDA-approved for human use as a drug. FDA PCAC materials state that the reviewed CJC-1295-related substances are not components of an FDA-approved drug, and FDA lists CJC-1295 among nominated-but-withdrawn bulk substances with safety concerns. [17][16][15]

Route	FDA drug approval	503A compounding
Injectable	Not Approved The openFDA Drugs@FDA query for CJC-1295 returned no matching approved drug product, and FDA PCAC materials state that the reviewed CJC-1295-related substances are not components of an FDA-approved drug. [17][16]	Flagged FDA's safety-risk page lists CJC-1295 under bulk substances nominated but withdrawn and flags immunogenicity for certain routes, peptide-related impurities, API-characterization complexity, serious adverse events including increased heart rate and systemic vasodilatory reaction, and limited clinical data. [15][16]

Injectable

FDA drug approval

Not Approved

The openFDA Drugs@FDA query for CJC-1295 returned no matching approved drug product, and FDA PCAC materials state that the reviewed CJC-1295-related substances are not components of an FDA-approved drug. [17][16]

503A compounding

Flagged

FDA's safety-risk page lists CJC-1295 under bulk substances nominated but withdrawn and flags immunogenicity for certain routes, peptide-related impurities, API-characterization complexity, serious adverse events including increased heart rate and systemic vasodilatory reaction, and limited clinical data. [15][16]

International

International status is route-, product-, and claim-specific. No country-specific therapeutic approval outside the United States is established in this review.

Sports & competition

Sports competition: prohibited under WADA S2 growth hormone releasing factors. The prohibition applies regardless of whether the product is labeled as research use, compounded, or clinic supplied. [18]

How it works

The starting point is the natural GHRH signal. GHRH normally tells pituitary somatotroph cells to release growth hormone. CJC-1295 is designed to imitate and extend that signal rather than replace GH itself. [2][16]

The albumin-binding feature changes the pharmacology. Jette and colleagues used a maleimido albumin-binding strategy, and FDA review materials describe the MPA group binding covalently to albumin's cysteine-34 residue. In plain terms, albumin works like a circulation carrier that can make the signal last much longer. [3][16]

In human studies, that design translated into sustained endocrine biomarkers: GH rose for days, IGF-1 rose for longer, and pulsatile GH secretion was preserved while baseline trough GH increased. Those details matter because a flat GH replacement exposure and a stimulated pituitary signal are not the same thing. [1][2]

The limitation is translation. GH and IGF-1 sit upstream of body composition, recovery, and sleep biology, but raising upstream biomarkers does not automatically prove a downstream outcome. Stronger claims require outcome trials, long-term safety data, and route-specific product-quality evidence. [4][15]

Research gaps & open questions

What the current literature has not yet settled about CJC-1295:

Outcome trials are the largest gap. Confidence would change with controlled human data showing whether CJC-1295 improves body composition, sleep, recovery, or deficiency-related outcomes beyond biomarker changes. [1]

Long-term safety is unresolved, especially for repeated non-study use, high or sustained IGF-1 exposure, endocrine disease, cancer or growth-factor-sensitive conditions, glucose dysregulation, and special populations. [1][15]

Product-quality evidence is decision-changing because FDA flags peptide-related impurities, immunogenicity, aggregation, and API-characterization concerns for compounded CJC-1295-related substances. [15][16]

DAC and no-DAC forms need separate route, timing, and safety reviews. Future UI should not collapse CJC-1295 and Modified GRF 1-29 into the same schedule or evidence label. [16][3]

Common questions

What is CJC-1295 investigated for?

CJC-1295 is commonly investigated or discussed across GH-axis stimulation, body-composition outcomes, exercise recovery, sleep quality, and anti-aging or vitality support. The strongest direct support is GH and IGF-1 biomarker response; the other outcome areas need their own human evidence. [1][2][5][4]

Is CJC-1295 the same as CJC-1295 without DAC?

No. CJC-1295 is the long-acting albumin-binding form. CJC-1295 without DAC is usually discussed as Modified GRF 1-29, a shorter-acting GHRH analog with different scheduling and evidence questions. [3][16]

What is the CJC-1295 dose?

Common CJC-1295 protocols usually center on 2 mg per dose, 2-3 times weekly, before bed, for 8-12 weeks. [1][16]

Is CJC-1295 safe?

The safety answer is not settled. Early healthy-adult studies reported no serious adverse reactions, but FDA identifies limited clinical data, serious adverse events associated with CJC-1295, and compounding concerns involving immunogenicity, impurities, and API characterization. [1][15]

Can CJC-1295 be combined with ipamorelin?

CJC-1295 and ipamorelin act through different GH-axis pathways, but combination-level efficacy, safety, dosing, lab monitoring, and sports status need a separate stack review before the pair is treated as recommended. [1][15][18]

Myths & misconceptions

Myth

If CJC-1295 raises GH and IGF-1, it is proven for muscle, sleep, recovery, and anti-aging.

Reality

The reviewed human data prove endocrine biomarker response, not the full set of marketed outcomes. Each downstream claim needs its own human outcome evidence. [1][4]

Myth

Long-acting CJC-1295 and CJC-1295 no DAC are basically the same.

Reality

They should be treated as different pharmacology problems. FDA review materials distinguish DAC and non-DAC CJC-1295-related substances and caution that albumin-binding pharmacology cannot be extrapolated to the non-DAC form. [16]

Myth

Research-use or compounded CJC-1295 is safe if the schedule looks common.

Reality

A familiar schedule does not solve product identity, sterility, peptide-related impurities, aggregation, immunogenicity, API characterization, or long-term endocrine safety. [15][16]

History & discovery

CJC-1295 moved from albumin-binding GHRH analog design into early human GH-axis trials, then into discontinued drug-development and later compounding/research-market visibility. Its public reputation now runs ahead of completed clinical outcome evidence. [3][1][15]

Jette and colleagues identified CJC-1295 as a long-lasting hGRF(1-29) analog after testing maleimido hGRF-albumin bioconjugates in vitro and in rats. [3]

Randomized, placebo-controlled ascending-dose studies in healthy adults reported sustained GH and IGF-1 increases after subcutaneous CJC-1295, and a separate study reported preserved GH pulsatility. [1][2]

A serum proteomics study examined biomarker changes after CJC-1295 exposure, while analytical work identified CJC-1295 in an unknown pharmaceutical preparation and framed it as a WADA-prohibited GH-releasing factor. [4][13]

FDA PCAC materials evaluated five CJC-1295-related bulk substances for 503A compounding and FDA's safety-risk page lists CJC-1295 under nominated-but-withdrawn substances. WADA's 2026 prohibited-list materials identify CJC-1295 as a prohibited growth hormone releasing factor. [16][15][18]

Published research 18 studies

[1]

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

PubMed / Journal of Clinical Endocrinology and Metabolism, 2006. human clinical.

[2]

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

PubMed / Journal of Clinical Endocrinology and Metabolism, 2006. human clinical.

[3]

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.

PubMed / Endocrinology, 2005. animal.

[4]

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

PubMed Central / Growth Hormone & IGF Research, 2009. human clinical.

[5]

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.

PubMed / American Journal of Physiology-Endocrinology and Metabolism, 2006. animal.

[6]

Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.

PubMed / JBJS Reviews, 2026. review.

[7]

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

PubMed / Sports Medicine, 2026. review.

[8]

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

PubMed / American Journal of Sports Medicine, 2026. review.

[9]

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.

PubMed / Substance Use & Misuse, 2016. review.

[10]

Advances in the detection of growth hormone releasing hormone synthetic analogs.

PubMed / Drug Testing and Analysis, 2021. ex vivo.

[11]

An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.

PubMed / Drug Testing and Analysis, 2019. ex vivo.

[12]

A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.

PubMed / Drug Testing and Analysis, 2019. ex vivo.

[13]

Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.

PubMed / Drug Testing and Analysis, 2010. regulatory.

[14]

Glycine-modified growth hormone secretagogues identified in seized doping material.

PubMed / Drug Testing and Analysis, 2019. regulatory.

[15]

Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

U.S. Food and Drug Administration. regulatory.

[16]

FDA Evaluation of CJC-1295 Related Bulk Drug Substances for the December 4, 2024 Pharmacy Compounding Advisory Committee Meeting

U.S. Food and Drug Administration, 2024. regulatory.

[17]

openFDA Drugs@FDA query for CJC-1295

openFDA / U.S. Food and Drug Administration. database query.

[18]

2026 Prohibited List: International Standard

World Anti-Doping Agency, 2025. official guidance.